NCT06578559
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06578559
Title Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET)
Acronym BRICKET
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
L'Azienda Ospedaliero Universitaria di Cagliari Monserrato CA 09042 Italy Details
Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" Irccs Irst Meldola FC 47014 Italy Details
Fondazione Casa Sollievo Della Sofferenza - Irccs San Giovanni Rotondo FG 71013 Italy Details
Pia Fondazione di Culto e di Religione Cardinale G. Panico Tricase LE 73039 Italy Details
IRCCS Istituto Nazionale dei Tumori di Milano Milan MI 20133 Italy Details
Istituto Oncologico Veneto Irccs Padua PD 35128 Italy Details
Azienda Ospedaliero-Universitaria Pisana Pisa PI 56126 Italy Details
Nuovo Ospedale di Prato S. STEFANO Prato PO 59100 Italy Details
AUSL Romagna Ravenna RA 48121 Italy Details
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Roma RM 00168 Italy Details
A.O.U. Citta Della Salute E Della Scienza Di Torino Presidio Molinette Turin TO 10126 Italy Details
Azienda Sanitaria Universitaria Friuli Centrale Udine UD 33100 Italy Details
Azienda Ospedaliera Universitaria degli Studi di Campania L. Vanvitelli Naples 80131 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field